# First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

> **NCT07686068** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **VelaVigo Bio Inc** · enrollment: 260 (estimated)

## Conditions studied

- Participants With Advanced Solid Tumor Malignancies

## Interventions

- **DRUG:** VBC106

## Key facts

- **NCT ID:** NCT07686068
- **Lead sponsor:** VelaVigo Bio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-18
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686068, "First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*